Jonathan Zalevsky - Nektar Therapeutics President
| NKTR Stock | USD 0.99 0.06 6.56% |
President
Dr. Jonathan Zalevsky is Senior Vice President Research and Chief Scientific Officer of the Company. Dr. Zalevsky joined Nektar inJuly 2015as Vice President of Biology and Preclinical Development to lead biological and translational research and guide strategy for the Nektar discovery portfolio. During his tenure at the company, Dr. Zalevsky expertise in immunology, as well as his experience across biological modalities and therapeutic areas, have helped fuel the growth of the company immunooncology and immunology pipeline since 2017.
| Age | 50 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 |
| Phone | 415 482 5300 |
| Web | https://www.nektar.com |
Latest Insider Transactions
Zalevsky led the discovery and preclinical development for NKTR358 and NKTR262 . Prior to joining Nektar, Dr. Zalevsky had over 15 years of experience within both large pharmaceutical and small biotechnology companies. Previously, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to latestage development and launched products. Prior to working at Takeda, Dr. Zalevsky held a number of research and development positions at Xencor, where he was responsible for the discovery and development of Xencor first four clinicalstage assets.Jonathan Zalevsky Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Zalevsky against Nektar Therapeutics stock is an integral part of due diligence when investing in Nektar Therapeutics. Jonathan Zalevsky insider activity provides valuable insight into whether Nektar Therapeutics is net buyers or sellers over its current business cycle. Note, Nektar Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nektar Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Zalevsky over a week ago Disposition of 51115 shares by Jonathan Zalevsky of Nektar Therapeutics at 0.94 subject to Rule 16b-3 | ||
Jonathan Zalevsky over a year ago Sale by Jonathan Zalevsky of 9791 shares of Nektar Therapeutics |
Nektar Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2264) % which means that it has lost $0.2264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6163) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/02/2025, Return On Tangible Assets is likely to grow to -0.76. In addition to that, Return On Capital Employed is likely to grow to -0.34. At this time, Nektar Therapeutics' Total Assets are relatively stable compared to the past year. As of 01/02/2025, Non Currrent Assets Other is likely to grow to about 8.3 M, while Other Assets are likely to drop slightly above 2.5 M.Similar Executives
| Found 2 records | PRESIDENT Age | ||
| Timothy Keutzer | Spero Therapeutics | 57 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.23 |
Nektar Therapeutics Leadership Team
Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer | ||
| Vivian Wu, Director Affairs | ||
| Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs | ||
| Mark Wilson, Chief Sec | ||
| Sandra Gardiner, Interim Officer | ||
| Kevin Brodbeck, VP Operations | ||
| Mark JD, Chief VP | ||
| Howard Robin, CEO and President and Director | ||
| MD LAc, Chief Officer | ||
| Brian MD, Chief Officer | ||
| John Northcott, Strategic Advisor | ||
| Loui Madakamutil, VP Research | ||
| Robert Bacci, Senior Operations | ||
| Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin. |
Nektar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.81) % | ||||
| Operating Margin | (1.42) % | ||||
| Current Valuation | 133.14 M | ||||
| Shares Outstanding | 184.46 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 76.59 % | ||||
| Number Of Shares Shorted | 4.4 M | ||||
| Price To Earning | 8.02 X |
Pair Trading with Nektar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Nektar Stock
Moving against Nektar Stock
| 0.88 | BNR | Burning Rock Biotech | PairCorr |
| 0.85 | XGN | Exagen Inc | PairCorr |
| 0.83 | DYAI | Dyadic International | PairCorr |
| 0.64 | BMY | Bristol Myers Squibb | PairCorr |
| 0.63 | DVAX | Dynavax Technologies | PairCorr |
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.